Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 5
2016 2
2017 4
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Charles Coombes R; IRIStrial participants. Palmieri C, et al. Breast Cancer Res Treat. 2018 Jan;167(1):407. doi: 10.1007/s10549-017-4539-3. Breast Cancer Res Treat. 2018. PMID: 29071491 Free PMC article.
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, Kenny LM. Palmieri C, et al. Breast Cancer Res Treat. 2017 Nov;166(2):527-539. doi: 10.1007/s10549-017-4427-x. Epub 2017 Aug 9. Breast Cancer Res Treat. 2017. PMID: 28795252 Free PMC article. Clinical Trial.
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC; IRIS trial participants. Palmieri C, et al. Breast Cancer Res Treat. 2017 Sep;165(2):343-353. doi: 10.1007/s10549-017-4328-z. Epub 2017 Jun 13. Breast Cancer Res Treat. 2017. PMID: 28612226 Free PMC article.
NY-ESO-1 expression in DCIS: A new predictor of good prognosis.
Coombes RC, Caballero OL, Shousha S, Ghaem-Maghami S, Woodley-Barker L, Wilhelm-Benartzi CS, Neville AM. Coombes RC, et al. Oncoscience. 2017 Apr 28;4(3-4):33-40. doi: 10.18632/oncoscience.348. eCollection 2017 Mar. Oncoscience. 2017. PMID: 28540335 Free PMC article.
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ. Palmieri C, et al. Oncotarget. 2016 Mar 15;7(11):13209-20. doi: 10.18632/oncotarget.4801. Oncotarget. 2016. PMID: 26334099 Free PMC article.
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJH, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JMS, Bliss JM, Coombes RC; PathIES Sub-Committee. Speirs V, et al. Ann Oncol. 2015 Sep;26(9):1890-1897. doi: 10.1093/annonc/mdv242. Epub 2015 May 22. Ann Oncol. 2015. PMID: 26002610 Free article. Clinical Trial.
11 results